MedVellum
MedVellum
Back to Library
Paediatrics
Respiratory
Gastroenterology
EMERGENCY

Cystic Fibrosis

High EvidenceUpdated: 2025-12-23

On This Page

Red Flags

  • Meconium Ileus (Newborn intestinal obstruction)
  • Hemoptysis (Massive >240ml - Emergency Embolisation)
  • Pneumothorax (Sudden breathlessness -> Chest Drain)
  • DIOS (Distal Intestinal Obstruction Syndrome - Acute Abdomen)
  • Rapid Decline in FEV1 (Infection or Rejection?)
  • Hyponatremic Dehydration (Salty Baby in Heatwave)
Overview

Cystic Fibrosis (CF)

1. Overview

Summary

Cystic Fibrosis (CF) is the most common life-limiting autosomal recessive condition in Caucasian populations (1 in 2,500 births). It is a multisystem disorder affecting the exocrine glands, but mortality is primarily driven by progressive bronchiectasis and lung failure.

The landscape of CF has been revolutionized by CFTR modulators (Kaftrio), transforming it from a fatal disease of childhood to a chronic condition of adulthood.

Key Facts

  • Genetics: Autosomal Recessive (1 in 25 people are carriers).
  • Population: Carrier frequency is highest in Northern Europeans.
  • Survival: Median predicted survival for a child born today is >50 years (possibly normal with modulators).

Systemic Overview Table

SystemDefectResult
LungsThick MucusInfection / Bronchiectasis
PancreasBlocked DuctsMalabsorption / Diabetes
LiverBile StasisCirrhosis
GutBlockageMI / DIOS
ReproCBAVDMale Infertility
SkinSalt LossHyponatremia

Clinical Pearls

"The Salty Kiss": The earliest historical description of CF. "Woe to the child who tastes salty from a kiss on the brow, for he is cursed and soon must die." High sweat chloride remains the diagnostic gold standard.

"Meconium Ileus Rule": 90% of babies with meconium ileus have CF. But only 15% of CF babies have meconium ileus.

Historical Perspective

From death sentence to middle age.

  • 1938: First described by Dorothy Andersen ("Cystic Fibrosis of the Pancreas").
  • 1950s: Sweat test developed.
  • 1989: CFTR gene discovered (Toronto).
  • 2012: Kalydeco (First modulator) approved.
  • 2020: Kaftrio approved (The game changer).

2. Genetics: The Mutation Spectrum

The CFTR Gene

Location: Long arm of Chromosome 7 (7q31.2). Function: Encodes a Chloride channel regulated by cAMP.

The 6 Classes of Mutations

Not all CF is the same.

ClassDefect MechanismSeverityExampleModulator?
INo Protein (Stop codon)SevereG542XDifficult
IITrafficking (Misfolded, stuck in ER)SevereF508delYES (Kaftrio)
IIIGating (Reaches surface, won't open)SevereG551DYES (Kalydeco)
IVConductance (Narrow channel)MildR117HYes
VSplicing (Reduced quantity)Mild-Yes
VIStability (High turnover)Severe-Yes

Note: F508del accounts for >70% of alleles worldwide.

Genotype-Phenotype Correlation

  • Pancreatic Status: Highly correlated with genotype. Class I-III are usually Pancreatic Insufficient (PI). Class IV-V are often Pancreatic Sufficient (PS).
  • Lung Function: Less predictable. Environmental factors (smoke, infection) play a huge role.

The Maths of Inheritance

Autosomal Recessive Rules.

  • Carrier + Carrier:
    • 25% Affected (CF).
    • 50% Carrier (Healthy).
    • 25% Non-Carrier (Healthy).
  • Risk: If a sibling has CF, the healthy sibling has a 2/3 chance of being a carrier.

3. Pathophysiology: The "Low Volume" Hypothesis

The Cascade of Failure

  1. The Defect: CFTR channel fails to pump Chloride (Cl-) out of the cell into the airway lumen.
  2. The Consequence: Because Cl- stays in, Sodium (Na+) is hyper-absorbed back into the cell (via ENaC channel) to balance charge.
  3. The Water: Water follows Sodium (osmosis). It leaves the airway lumen.
  4. The Result: The "Airway Surface Liquid" (ASL) layer dries out.
  5. Mucociliary Failure: The cilia are crushed by thick, dehydrated mucus. They cannot beat.
  6. Infection: Bacteria (Staph, Pseudomonas) are trapped and colonize the static mucus.
  7. Destruction: Chronic Neutrophilic Inflammation -> Elastase release -> Bronchiectasis.

4. Clinical Features by System

Respiratory

  • Cough: Chronic, wet, purulent.
  • Infection: Recurrent exacerbations.
  • Bronchiectasis: Permanent dilation of airways (Signet ring sign on CT).
  • Haemoptysis: Bronchial arteries bleed.

The Nose (Upper Airway)

The forgotten airway.

  • Polyps: Benign swellings. Cause obstruction/loss of smell.
  • Treatment: Steroid drops (Betnesol) or Surgery (FESS). Use of modulators often shrinks them!
  • Sinusitis: Chronic reservoir for Pseudomonas.

Digital Clubbing

The Schamroth Sign.

  • Mechanism: Platelet derived growth factor (PDGF) clumping in the fingers due to right-to-left shunting?
  • Significance: Universal in advanced CF. If a "CF" child doesn't have clubbing, question the diagnosis (or they are very mild/screened early).
  • Hypertrophic Osteoarthropathy (HPOA): Painful periostitis of wrists/ankles (associated with clubbing).

Gastrointestinal

  • Meconium Ileus: 15% of newborns. Sticky meconium blocks terminal ileum.
  • Pancreatic Insufficiency (85%): Blocked ducts causing autodigestion of pancreas -> Fibrosis -> No enzymes.
  • Steatorrhoea: Large, pale, greasy, foul-smelling stools (fat malabsorption).
  • CFRD: CF Related Diabetes (Insulin deficiency due to fibrosis + Insulin resistance).
  • DIOS: Distal Intestinal Obstruction Syndrome (The adult equivalent of meconium ileus).
    • Mechanism: Sticky poop blocks the ileocaecal valve.
    • Trigger: Dehydration, Missed Creon.
    • Treatment: Hydration + Gastrografin (Oral contrast that draws water into gut). Surgery is a last resort.

Reproductive

  • Men: 98% have Congenital Bilateral Absence of Vas Deferens (CBAVD). Infertility (Azoospermia). Sexual function is normal.
  • Women: Viscid cervical mucus may reduce fertility, but most can conceive naturally.

Other Systems

  • Sweat: Salty sweat (Risk of Hyponatremic Dehydration in heatwaves).
  • Liver: Focal Biliary Cirrhosis (CFLD).
    • Pathology: Bile is thick -> plugs bile ducts -> cirrhosis -> Portal Hypertension.
    • Management: Ursodeoxycholic Acid (Urso). Monitor LFTs.
  • Bones: Osteopenia/Osteoporosis.
    • Cause: Vit D deficiency + Inflammation + Steroids.
    • Tx: Bisphosphonates if severe.

5. Diagnosis

Newborn Screening (Guthrie Test)

  1. Day 5 Heel Prick: Measures IRT (Immunoreactive Trypsinogen).
  2. Mechanism: IRT leaks from the blocked pancreas into blood.
  3. High IRT?: Proceed to DNA mutation analysis.

Sweat Test (The Gold Standard)

Pilocarpine Iontophoresis.

  • Method: Drive drug into skin to stimulate sweat -> Collect sweat -> Measure Chloride.
  • Normal: <30 mmol/L.
  • Equivocal/Carrier: 30-59 mmol/L.
  • Cystic Fibrosis: >60 mmol/L.
  • False Positives: Malnutrition, Eczema, Adrenal Insufficiency, Hypothyroidism.
  • Rules: Sweat quantity must be sufficient (>75 mg).

Genetic Testing

  • Standard panels screen for the top 50 mutations.
  • If Sweat Test is positive but only 1 mutation found -> Full Gene Sequencing required.

6. Management: The CFTR Modulators

The Revolution

Treating the cause, not just symptoms.

Drug NameComponentsTarget MutationEffect
Ivacaftor (Kalydeco)IvacaftorG551D (Class III)"The Opener". Potentiator. Forces the gate open.
Lumacaftor / Ivacaftor (Orkambi)Lumacaftor + IvaF508del (Homozygous)"The Fixer + Opener". Corrects folding.
Kaftrio (Trikafta)Elexacaftor + Tezacaftor + IvaF508del (At least 1 copy)The Miracle. "Triple Therapy".

Kaftrio Impact

  • FEV1: Increases by ~14%.
  • Exacerbations: Reduced by 60-70%.
  • BMI: Massive weight gain (patients need diet advice!).
  • Sweat Chloride: Drops to near normal levels.

Modulator Side Effects

  • Liver: Transaminase elevation (Check LFTs every 3 months).
  • Eyes: Cataracts in children (Check eyes annually).
  • Mental Health: Anxiety/Depression reported (Brain fog).

The Cost of Survival

Economics vs Ethics.

  • Price Tag: Kaftrio costs ~$100k-$200k per patient per year.
  • Access: Available in UK/USA/Europe. Developing world patients have no access ("The Genetic Lottery").
  • Generic: Activists fight for generic production (Vertex patent challenge).

The Future: Gene Therapy

For the 10% who can't take Modulators.

  • Method: Inhaled Viral Vectors or Lipid Nanoparticles to deliver correct mRNA/DNA.
  • Challenge: Getting through the thick mucus to the epithelial cells.
  • Status: Clinical Trials ongoing (Spirovant, Translate Bio).

7. Management: Respiratory

Airway Clearance (Physiotherapy)

The daily grind. 20-30 mins, twice a day. Forever.

  • Infants: Percussion / Tipping? (Old school). Now mostly bouncy bouncing.
  • Children/Adults:
    • PEP Mask (Positive Expiratory Pressure): Splints airways open.
    • Flutter / Acapella: Oscillating PEP (shakes the mucus loose).
    • Autogenic Drainage: Breathing control technique.
    • The Vest: High frequency chest wall oscillation (Common in USA).

Lung Function Grading (FEV1)

  • Normal: >80% predicted.
  • Mild: 60-80%.
  • Moderate: 40-60%.
  • Severe: <40% (Transplant assessment begins).

The "Active Cycle of Breathing" (ACBT)

The most common technique.

  1. Breathing Control: Relaxed tummy breathing.
  2. Thoracic Expansion: Deep breath in + Hold 3 secs (gets air behind mucus).
  3. Huffing: Forced Expiration Technique (Move mucus up).
  4. Cough: Clear it out.

Exercise as Physio

  • Benefit: Improves muscle strength, expands chest, mobilises mucus.
  • Rule: "If you do 30 mins of vigorous sport (sweating/breathless), you can skip one physio session." (Varies by centre!).

Mucolytics

Thinning the glue.

  1. DNase (Dornase Alfa): Enzyme that digests the DNA released by dead neutrophils (which makes mucus sticky). Inhaled daily.
  2. Hypertonic Saline (7%): Draws water back into the airway (Osmosis) to rehydrate the ASL. Must give Salbutamol first to prevent bronchospasm.

Antibiotics

  • Prophylaxis: Flucloxacillin (UK) to prevent Staph until age 3. Azithromycin (3x weekly) for anti-inflammatory effect.
  • Exacerbations: 2 weeks of IV antibiotics (often home IVs via Port-a-cath).
  • Nebulized: Tobramycin / Colomycin for chronic Pseudomonas suppression.

Nebulizer Hygiene

Avoiding self-infection.

  • Risk: Nebulizer pots are wet, warm breeding grounds for Pseudomonas or Serratia.
  • Protocol: Wash after every use. Steam sterilize (microwave bags) or boil daily. Replace pots every 3 months.

Totally Implantable Venous Access Devices (TIVAD)

The Port-a-Cath.

  • Indication: Difficult venous access + Frequent IV courses (>3-4 per year).
  • Placement: Subcutaneous reservoir on chest wall, catheter into SVC.
  • Maintenance: Monthly flush (Heparin).
  • Risk: Infection (Line Sepsis).

8. Management: Nutrition & Pancreas

Creon (Enzyme Replacement)

Without this, food goes straight through.

  • Dose: Titrated to fat content of meal.
  • Rule: Taken with every meal/snack containing fat.
  • Exceptions: Fruit, Juice, Jelly sweets, Cordial (No fat = No Creon).
  • Signs of Under-dosing: Abdominal pain, bloating, floating stools.
  • Signs of Over-dosing: Fibrosing Colonopathy (Rare strictures).

Diet

  • High Calorie: 120-150% of RDA. "Fat is your friend".
    • Supplements: High energy drinks (Scandishake/Fortisip).
    • Tube Feeding: Overnight Gastrostomy (PEG) feeding is common if weight gain is poor.
  • Salt: Extra salt supplements needed in hot weather/sport.
  • Vitamins: Fat soluble (ADEK) supplements daily (Dalavit/Abidec).

Salt Supplementation

The forgotten nutrient.

  • Loss: CF sweat has high salt concentration. In hot weather or sport, they lose massive amounts.
  • Risk: Hyponatremic Dehydration (Pseudo-Bartter's syndrome).
  • Dose: Sodium Chloride tablets or liquid added to milk for babies.

9. Microbiology: The Villains

Pseudomonas aeruginosa

The enemy.

  • Impact: Once established ("Mucoid"), lung function decline accelerates.
  • Eradication Protocol: If new growth -> Oral Ciprofloxacin + Nebulized Colomycin for 3 months. Aim to clear it before it becomes mucoid.
    • Failure: If it becomes chronic, the patient needs long-term suppression (Nebs forever).
    • Cross-Infection: Never mix patients with different strains.

The Sputum Sample

The most important test.

  • Protocol: Every clinic visit (even if well).
  • Technique: Cough swab for babies, Sputum pot for older kids.
  • Why?: To catch Pseudomonas early (before it becomes mucoid).

Drug Toxicity

The price of antibiotics.

  • Aminoglycosides (Gentamicin/Tobramycin): Ototoxic (Deafness) and Nephrotoxic (Kidney failure).
  • Monitoring: Trough levels must be checked religiously.
  • Hearing: Annual Audiometry is mandatory.

Vaccination Schedule

  • Flu Vaccine: Annual (Essential).
  • Pneumococcal: PCV13 + PPSV23.
  • Varicella: Check immunity (Chickenpox can be severe).
  • COVID-19: Prioritized group.

Burkholderia cepacia complex

The disaster.

  • Transplant: Often an absolute contraindication to lung transplant due to risk of fatal post-op sepsis ("Cepacia Syndrome").
  • Segregation: Strict isolation in clinics. CF patients never meet other CF patients face-to-face.

Non-Tuberculous Mycobacteria (NTM)

  • M. abscessus: Very hard to treat. Requires 18 months of triple antibiotics.

10. Complications & Organs

The Liver

  • CFLD: Bile is thick -> plugs bile ducts -> cirrhosis.
  • Ursodeoxycholic Acid: Used to improve bile flow.

CF Related Diabetes (CFRD)

Not Type 1, Not Type 2.

  • Pathology: Fibrosis destroys Islet cells (Insulin deficiency) + Infection causes Insulin Resistance.
  • Screening: Annual OGTT (Oral Glucose Tolerance Test) from age 10. (HbA1c is unreliable in CF due to RBC turnover).
  • Treatment: Insulin. Oral hypoglycemics (Metformin) don't work well.
  • Diet: Do NOT restrict calories. Give Insulin to match the high-calorie diet.

The Bones

  • Bone Density: DEXA scans every 1-2 years from adolescence.

  • Risk: Steroid use + Malabsorption + Inflammation.

  • Action: Chest drain. Pleurodesis needed if recurrent.

COVID-19 and Shielding

The Surprise Result.

  • Fear: Early pandemic prediction was that CF patients would die in huge numbers.
  • Reality: Outcomes were surprisingly good (similar to non-CF).
  • Shielding: 2 years of isolation caused significant deconditioning and mental health decline, even if it prevented COVID.

Haemoptysis

  • Minor: Streaks. Treat infection.
  • Major: >240ml. bronchial artery embolisation required. STOP NSAIDs and Physio.

Lung Transplantation

The last resort.

  • Criteria: FEV1 <30%, Rapid decline, Massive haemoptysis.
  • Contraindications: Burkholderia cenocepacia, NTM (sometimes), Poor adherence, BMI <18 or >35.
  • Outcome: Median survival ~5-8 years post-transplant.
  • Trade-off: Swapping one disease (CF) for another (Immunosuppression/Rejection).

End of Life Care

The difficult conversation.

  • Advanced Directives: Should be discussed before acute failure.
  • NIV as Ceiling: Often used for symptom relief (breathlessness) at end of life, not just for rescue.
  • Palliative Team: Involve early for symptom control (Opioids for dyspnea).

11. Adolescence & Transition

The Transfer

  • Moving from Pediatric (Family-centered) to Adult (Patient-centered) care.
  • Timing: Process starts at 14, transfer at 16-18.
  • Topics:
    • Fertility: Discuss CBAVD with boys.
    • Genetics: Carrier testing for partners.

    The Psychological Burden

A 2-hour daily routine.

  • The Grind: Physio x2, Nebs x2, Creon x4, Antibiotics, Vitamins, Modulators.
  • Depression: High prevalence in adolescents.
  • "Survivor Guilt": Losing friends to CF while you survive (especially post-transplant or on Kaftrio).

Travel with CF

The Logistics.

  • Insurance: Very expensive. Declare everything.
  • Flight O2: Hypoxia at altitude. If sea-level sats <95%, may need in-flight oxygen (Fit-to-fly test).
  • Medications: Carry in hand luggage (avoid freezing in hold). Letter from consultant required.

Fertility Guide

Fertility Guide

The Conversation to have early.

  • Males: CBAVD (Congenital Bilateral Absence of Vas Deferens). The sperm are made in the testes but cannot get out.
    • Solution: Sperm retrieval (MESA/TESA) + ICSI (IVF). Success rates are high.
    • Contraception: Still needed! (STIs and the 2% chance of potency).
  • Females: Thick cervical mucus.
    • Pregnancy: High risk but managed. Need to stop some drugs (ACEi, certain antibiotics). Kaftrio safety in pregnancy is being studied (often continued).

Pregnancy Protocol (MDT Care)

  • Risks: Increased metabolic demand, reduced lung volume (baby pushes up diaphragm), GDM (Gestational Diabetes), Pre-term labour.
  • Outcome: Generally good if lung function >50% at start.
  • Breastfeeding: Encouraged (but baby needs sodium check as breast milk is low salt).

The Psychological Burden

Social Impact

Living a normal life.

  • School: Missed days for appointments/IVs. "Special consideration" for exams.
  • Work: Most adults work full time. Disclosure to employer is optional but recommended for appointments.
  • Sports: Highly encouraged! Natural airway clearance.

The "Annual Review" Checklist

The yearly MOT.

  1. Lungs: CXR, Spirometry, Sputum culture.
  2. Pancreas: OGTT (Diabetes screen), Faecal Elastase (if unsure).
  3. Liver: USS Liver (Cirrhosis check).
  4. Bones: DEXA Scan (Osteoporosis).
  5. Ears: Audiometry (Antibiotic damage).
  6. Nutriton: Dietician review (BMI check).
  7. Social: Psychology, School/Work performance.

Patient Instructions: Taking Creon

  1. Timing: Take with the first mouthful of food.
  2. Swallowing: Do not chew beads (They will ulcerate the mouth).
  3. Capsules: Can be opened and granules mixed with apple puree for babies.
  4. Dose: Adjust until poops are normal (brown logs).

Patient Instructions: Using a Flutter

  1. Technique: Exhale slowly through device.
  2. Sensation: Feel the vibration in the chest wall.
  3. Action: Cough afterwards to clear the loosened phlegm.

12. References
  1. Cystic Fibrosis Trust: Standards of Care (2023).
  2. ECFS Guidelines: Best Practice Guidelines (2018 Revision).
  3. NICE NG78: Cystic Fibrosis diagnosis and management (2017).
  4. Vertex Pharmaceuticals: Trikafta Prescribing Information (2020).
  5. Ramsey BW et al: A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. NEJM 2011.
  6. Heijerman HGM et al: Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation. Lancet 2019.

Senior Editor: Dr. N. Goyal (Paediatrics). Guideline Check: NICE NG78 / ECFS verified.


Copyright: © 2025 MedVellum. All rights reserved. Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.

Last updated: 2025-12-23

At a Glance

EvidenceHigh
Last Updated2025-12-23
Emergency Protocol

Red Flags

  • Meconium Ileus (Newborn intestinal obstruction)
  • Hemoptysis (Massive &gt;240ml - Emergency Embolisation)
  • Pneumothorax (Sudden breathlessness -> Chest Drain)
  • DIOS (Distal Intestinal Obstruction Syndrome - Acute Abdomen)
  • Rapid Decline in FEV1 (Infection or Rejection?)
  • Hyponatremic Dehydration (Salty Baby in Heatwave)

Clinical Pearls

  • **"Meconium Ileus Rule"**: 90% of babies with meconium ileus have CF. But only 15% of CF babies have meconium ileus.
  • Full Gene Sequencing required.
  • Oral Ciprofloxacin + Nebulized Colomycin for 3 months. Aim to clear it before it becomes mucoid.
  • **Copyright**: © 2025 MedVellum. All rights reserved.

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines